Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 10/20 | 0.58 |
| ▸ | CDK2 | P24941 | 10/20 | 0.58 |
| ▸ | CCNA1 | P78396 | 10/20 | 0.58 |
| ▸ | AURKA | O14965 | 9/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | EP300 | Q09472 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15899875 | 0.82 | CDK2 (0.83) | CCNA2CDK2CCNA1AURKABRD4 | |
| SCHEMBL3611357 | 0.80 | POLB (0.47) | CCNA2CDK2CCNA1AURKAPOLB | |
| SCHEMBL2921282 | 0.74 | CDK2 (1.00) | CCNA2CDK2CCNA1AURKA | |
| SCHEMBL1464582 | 0.73 | CCNA2 (0.47) | CCNA2CDK2CCNA1AURKANPC1 | |
| SCHEMBL2923011 | 0.72 | CDK2 (1.00) | CCNA2CDK2CCNA1AURKABRD4 | |
| SCHEMBL2920110 | 0.71 | AURKA (0.69) | CCNA2CDK2CCNA1AURKAAURKB | |
| SCHEMBL2923899 | 0.70 | CCNA2 (0.61) | CCNA2CDK2CCNA1AURKA | |
| SCHEMBL2920175 | 0.70 | CCNA2 (0.72) | CCNA2CDK2CCNA1AURKABRD4 | |
| SCHEMBL2916913 | 0.70 | CCNA2 (0.72) | CCNA2CDK2CCNA1AURKANPC1 | |
| SCHEMBL2916923 | 0.70 | CCNA2 (0.76) | CCNA2CDK2CCNA1AURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750034-B2 | Aminocyclohexanes as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20090270467-A1 | Aminocyclohexanes as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK & CO., INC. (US) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270467-A1 | Aminocyclohexanes as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | DPP4, DPP3, DPP7 | CCNA2 1760/4885CDK2 736/4885CCNA1 2588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.